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ABSTRACT
A blinded, negative controlled, randomized interven-
tion study was undertaken to test the hypothesis that 
addition of meloxicam, a nonsteroidal anti-inflammato-
ry drug, to antimicrobial treatment of mild to moderate 
clinical mastitis would improve fertility and reduce the 
risk of removal from the herd. Cows (n = 509) from 
61 herds in 8 regions (sites) in 6 European countries 
were enrolled. Following herd-owner diagnosis of mild 
to moderate clinical mastitis within the first 120 d of 
lactation in a single gland, the rectal temperature, milk 
appearance, and California Mastitis Test score were 
assessed. Cows were randomly assigned within each 
site to be treated either with meloxicam or a placebo 
(control). All cows were additionally treated with 1 to 4 
intramammary infusions of cephalexin and kanamycin 
at 24-h intervals. Prior to treatment and at 14 and 
21 d posttreatment, milk samples were collected for 
bacteriology and somatic cell count. Cows were bred by 
artificial insemination and pregnancy status was sub-
sequently defined. General estimating equations were 
used to determine the effect of treatment (meloxicam 
versus control) on bacteriological cure, somatic cell 
count, the probability of being inseminated by 21 d 
after the voluntary waiting period, the probability of 
conception to first artificial insemination, the number 
of artificial insemination/conception, the probability of 
pregnancy by 120 or 200 d postcalving, and the risk of 
removal by 300 d after treatment. Cox’s proportional 
hazards models were used to test the effect of treat-
ment on the calving to first insemination and calving 
to conception intervals. Groups did not differ in terms 
of age, clot score, California Mastitis Test score, rectal 
temperature, number of antimicrobial treatments given 
or bacteria present at the time of enrollment, but cows 
treated with meloxicam had greater days in milk at 
enrollment. Cows treated with meloxicam had a higher 
bacteriological cure proportion than those treated 
with the placebo [0.66 (standard error = 0.04) versus 
0.50 (standard error = 0.06), respectively], although 
the proportion of glands from which no bacteria were 
isolated posttreatment did not differ between groups. 
No difference was observed in the somatic cell count 
between groups pre- or posttreatment. The proportion 
of cows that underwent artificial insemination by 21 d 
after the voluntary waiting period was unaffected by 
treatment. Treatment with meloxicam was associated 
with a higher proportion of cows conceiving to their first 
artificial insemination (0.31 versus 0.21), and a higher 
proportion of meloxicam-treated cows were pregnant 
by 120 d after calving (0.40 versus 0.31). The number 
of artificial inseminations required to achieve concep-
tion was lower in the meloxicam compared with control 
cows (2.43 versus 2.92). No difference was observed 
between groups in the proportion of cows pregnant by 
200 d after calving or in the proportion of cows that 
were culled, died, or sold by 300 d after calving (17% 
versus 21% for meloxicam versus control, respectively). 
It was concluded that use of meloxicam, in conjunction 
with antimicrobial therapy, for mild to moderate cases 
of clinical mastitis, resulted in a higher probability of 
bacteriological cure, an increased probability of concep-
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tion to first artificial insemination, fewer artificial in-
seminations, and a greater proportion of cows pregnant 
by 120 d in milk.
Key words: nonsteroidal anti-inflammatory drug, 
mastitis, cure, fertility
INTRODUCTION
Mastitis is a very common disease in dairy herds 
worldwide and incurs significant costs associated with 
treatment, production loss, and withdrawal of milk. 
Epidemiological studies have shown that mastitis has 
negative effects on reproductive performance, includ-
ing a longer interval from calving to conception, more 
services per conception (Barker et al., 1998; Schrick et 
al., 2001), lower conception rates (Santos et al., 2004; 
Lavon et al., 2011), and a higher risk of embryo loss 
(Chebel et al., 2004; McDougall et al., 2005). Effects 
were found for clinical mastitis caused by both gram-
positive and gram-negative pathogens; however, the ef-
fect size seems to be larger for gram-negative pathogens 
(Hertl et al., 2010).
The timing of the mastitis event relative to insemina-
tion appears to be important. For example, conception 
rates to first service were 29% for cows never diagnosed 
with clinical mastitis, 22% for cows diagnosed before 
AI, 10% for cows diagnosed after AI, and 38% for cows 
diagnosed following confirmation of pregnancy, respec-
tively (Santos et al., 2004). Similarly, the odds ratios for 
conception were 0.88 for cows diagnosed with clinical 
mastitis 31 to 60 d before AI, 0.81 for cows diagnosed 
≤30 d before AI, and 0.48 for cows diagnosed within 
21 d after AI, with only the latter group being different 
from unaffected cows (Loeffler et al., 1999a). Clinical 
mastitis reduces the hazard ratio (HR) of conception 
when calving to conception interval is modeled using 
survival analysis (HR = 0.65, 95% CI = 0.50–0.84; Su-
riyasathaporn et al., 1998).
Another effect of clinical mastitis is the higher risk 
of premature removal (culling or death) from the herd. 
Cows diagnosed with clinical mastitis are 1.3 to 1.5 
times more likely to be removed prematurely than 
cows not diagnosed with clinical mastitis (Beaudeau 
et al., 1995; Heuer et al., 1999; Santos et al., 2004). 
The hazard of culling associated with mastitis increases 
the later in lactation that mastitis is diagnosed, with 
the hazard ranging from 0.5 in early through to 2.5 in 
late lactation (Gröhn et al., 1997; Rajala-Schultz and 
Gröhn, 1999a), and the culling risk is also associated 
with the pathogen causing clinical mastitis (Gröhn et 
al., 2005).
Gram-negative infections release LPS (Bannerman et 
al., 2004), and both gram-positive and gram-negative 
infections increase the concentrations of IL-1 and tu-
mor necrosis factor α, which induce production of the 
enzyme cyclooxygenase (COX; Schmitz et al., 2004). 
Cyclooxygenase converts arachidonic acid into eico-
sanoids including prostaglandins, prostacyclins, and 
thromboxanes, which act as inflammatory mediators 
(Smith, 2005; Vangroenweghe et al., 2005). Cyclo-
oxygenase has 2 isoforms designated as COX-1 and 
COX-2. The COX-1 is mainly constitutively expressed 
and maintains gastrointestinal mucosal integrity, aids 
platelet aggregation, and enhances renal blood flow. 
The COX-2 isoform is inducible and is upregulated in 
response to inflammatory stimuli. Given the increases 
in pro-inflammatory eicosanoids during mastitis, use of 
anti-inflammatory therapy may be indicated to relieve 
the local and systemic clinical signs of inflammation 
and therefore hasten return to normal physiological 
function of the udder (Vangroenweghe et al., 2005; 
Suojala et al., 2013). Nonsteroidal anti-inflammatory 
drugs (NSAID) possess anti-inflammatory, antipyret-
ic, and analgesic properties (Smith, 2005). The NSAID 
may be nonselective, or selectively inhibit COX-1 or 
COX-2. Meloxicam is a preferential COX-2 inhibitor 
(Van Hecken et al., 2000; Lees et al., 2004) that has 
been demonstrated to reduce milk concentrations of 
thromboxane B2 during mastitis (Banting et al., 2000), 
to reduce the plasma concentrations of the PGF2α me-
tabolite PGFM in endotoxin-challenged cattle (Königs-
son et al., 2002), and to ameliorate clinical signs of 
mastitis in dairy cattle (Fitzpatrick et al., 2013). Thus, 
NSAID may ameliorate the negative effects of mastitis 
on reproduction via reduced PGF2α concentrations or 
via effects on gonadotrophin release, steroidogenesis, or 
both (Hockett et al., 2000, 2005; Lavon et al., 2011). 
A recent review of severe Escherichia coli mastitis rec-
ommends that NSAID be routinely used to supportive 
treatment in these cases (Suojala et al., 2013). Given 
that recommendation, the current study focused on 
mild to moderate mastitis. A recent field study on such 
cases has demonstrated that addition of meloxicam 
to antibiotic therapy resulted in a lower SCC and a 
lower culling proportion, particularly associated with 
failure to conceive (McDougall et al., 2009). Although 
reproductive outcomes were not specifically measured 
in that study, it was hypothesized that the NSAID may 
have been operating via reduction of negative effects of 
mammary inflammation on the reproductive tract.
The primary objective of the study was to assess if 
the combination of meloxicam and antibiotic therapy 
of mild to moderate cases of clinical mastitis diagnosed 
in the first 120 d of lactation would improve cow fertil-
ity compared with antibiotic therapy alone. Secondary 
objectives included assessment of the effect of addition 
of meloxicam on bacteriological cure and on the risk of 
removal within 300 d of calving.
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MATERIALS AND METHODS
The study was conducted using 509 cows sourced 
from 61 herds consisting of a total population of ap-
proximately 7,800 cows, across 10 sites in 6 countries 
(Belgium, France, Italy, Spain, the Netherlands, and 
United Kingdom). Sites were selected on a convenience 
basis, with the investigator at that site agreeing to fol-
low the protocol and to collect the required data. The 
investigator was asked to recruit up to 120 clinical cases 
from at least 3 farms. Herds were selected on the basis 
of being willing to follow the protocol, agreeing to allow 
access to cow level data, undertaking routine cow-level 
SCC assessment, and agreeing to allow collection of 
milk samples from enrolled cows. Additionally, herds 
were required to consist of at least 50 lactating cows 
and to milk twice daily. Robotic milking systems were 
excluded.
Herd owners were asked to present cows with signs 
of clinical mastitis (heat or swelling) in a single gland. 
Cows were excluded if they had been treated with anti-
microbials or NSAID in the preceding 14 d, had previ-
ously been enrolled in the study, had a SCC >200,000 
cells/mL at the 2 most recent DHIA tests in the cur-
rent lactation, or had already been diagnosed pregnant 
in the current lactation. Only cows less than 120 d of 
lactation were selected because a priori it was believed 
likely that the majority of cows would have had at 
least one breeding and be potentially pregnant after 
this time. The investigators examined eligible cows and 
excluded those with very severe teat-end lesions (Mein 
et al., 2001) or severe mastitis [pyrexia (>40.0°C), gross 
evidence of dehydration or recumbency]. A California 
Mastitis Test (CMT) was undertaken of the affected 
gland (scored as 0, trace, 1, 2, or 3), and the presence 
of clots in the milk scored on a none (0), flecks (1), 
or clots (2) scale. Following aseptic teat end prepara-
tion and discard of the first 3 strippings, a single milk 
sample (~10 mL) was collected by the investigator from 
the affected gland for microbiology and SCC. Samples 
were held on ice for transport between the farm and in-
vestigators facilities for a maximum of 8 h before being 
stored at −20°C until sent by courier to the laboratory 
(GD, Deventer, the Netherlands) monthly for process-
ing.
Cows were then treated with either meloxicam (0.5 
mg/kg or 2.5 mL/100 kg s.c.; Metacam 20 mg/kg solu-
tion for injection, Boehringer Ingelheim Animal Health, 
Germany; treatment) or the placebo (control), which 
was the vehicle for the meloxicam formulation and was 
visually indistinguishable from the treatment. A treat-
ment list was provided for each site, which consisted of 
a sequential list of numbers that correlated with a se-
ries of uniquely numbered, single-dose vials containing 
either the treatment or placebo. The list was generated 
by assigning at random within sequential pairs of num-
bers either the treatment or placebo. The investigator 
(veterinarian attending the cow) used the next sequen-
tially numbered vial to treat the next enrolled cow. The 
investigators, laboratory, and analysts were blinded to 
the identity of the treatments until after analysis.
Additionally, all enrolled quarters were infused with 
a combination of 200 mg of cefalexin monohydrate and 
133 mg (100,000 IU) of kanamycin monosulfate (Ubro-
lexin, Boehringer Ingelheim Animal Health) on 1 to 4 
occasions at 24-h intervals. Milk was discarded during 
treatment and for 10 milkings after the final treatment.
Single milk samples (~10 mL) were collected by the 
investigator or trained technician from all enrolled 
quarters for microbiology and SCC at 14 (±3) and 21 
(±3) d after initiation of treatment. The presence of 
clots in the milk (on a 0, 1, or 2 scale) was also recorded 
at these times. Herd owners were asked to record any 
subsequent disease diagnoses and treatments and to 
provide dates and reasons for culling, deaths, or sale 
of cows.
Herd owners were able to re-treat clinical cases where 
they perceived that the treatment had not resulted in 
clinical improvement of the affected gland. Treatment 
of other conditions with antibiotics or other products 
was allowed if required. Data concerning any treat-
ments for any conditions were recorded for the rest of 
the lactation.
Cows were bred and pregnancy tested as per normal 
herd practice and the data retrieved for analysis. All 
breeding dates for enrolled cows were recorded elec-
tronically or on paper-based recording systems (or 
both) on farm. Pregnancy testing occurred between 26 
and 270 d after insemination, and the pregnancy status 
(yes or no) and days pregnant were determined.
Prior to study initiation, approval from the Animal 
Ethics Committee of each country (where required) was 
sought and granted.
Microbiology
Upon receipt at the laboratory, the milk samples were 
stored at −20°C until processing. Processing occurred 
on average 2.5 d (SD = 0.4; range = 1 to 15) after re-
ceipt at the laboratory. Samples were then thawed and 
10 μL 5-phase streaked over an entire 6% sheep blood 
agar plate and incubated for 48 h at 37°C. At 24 and 
48 h, the presence or absence of colonies, the colony 
morphology and number of colonies were assessed. 
Prototheca, yeasts, and molds were identified by vi-
sual assessment of colony morphology and microscopic 
examination of a wet preparation at 400 times magni-
fication. From quarter samples with a SCC >100,000 
Journal of Dairy Science Vol. 99 No. 3, 2016
MELOXICAM IMPROVES FERTILITY IN COWS WITH MASTITIS 2029
cells/mL and with ≤3 colony types at 24 or 48 h (if no 
growth seen at 24 h), representative colonies of each 
type were analyzed by matrix-assisted laser desorption/
ionization-time of flight (MALDI-TOF) mass spec-
trometry (Seng et al., 2009; Bizzini and Greub 2010). 
When the result of initial culture was not definitive 
(no growth or growth of ≤10 cfu of “non-majors,” or 
growth of Corynebacterium spp. only) and the SCC was 
≥100,000 cells/mL (or the milk was visually abnormal), 
the milk sample was incubated at 37°C and was 5-phase 
streaked onto a 6% sheep blood agar plate and assessed 
after 21 ± 3 h at 37°C. A total of 0.4, 1.4, and 2.2% of 
samples had SCC <100,000 cells/mL and any growth 
at d 0, 14, and 21, respectively, and hence the growth 
was diagnosed on visual assessment and Gram stain. 
Where >3 colony types were present, double hemolytic 
colonies were assumed to be Staphylococcus aureus (n 
= 22 isolates; 3 pretretment and 19 posttreatment), 
otherwise the sample was defined as contaminated. 
Colonies visually assessed as Corynebacterium species 
were not tested further. Where the quarter-level SCC 
was <200,000 cells/mL, any isolates were identified 
only by visual observation. Where the MALDI-TOF 
result was unclear (i.e., no reliable identification or no 
peaks found) the identification was repeated, and if the 
result was not definitive, a Gram stain was performed 
and the result reported as a gram-positive cocci, (n = 
1), a gram-negative rod (n = 2), or a gram-positive rod 
(n = 2).
Bacteriological cure was defined as no isolation of the 
pathogen(s) (identified to the genus or species level) 
that were isolated pretreatment in either of the post-
treatment samples. So, for example, if E. coli had been 
isolated pretreatment and was not isolated in either of 
the posttreatment samples, the gland was defined as 
cured. A different bacterial genus or species may have 
been isolated at the posttreatment samples, but this 
did not affect the cure diagnosis. A new infection was 
defined as occurring where a gland previously defined 
as not infected (i.e., the gland was not defined infected 
at enrollment) was defined as infected at one or both 
time points after enrollment, or a different species or 
genus of bacteria was isolated from any posttreatment 
sample from that isolated pretreatment. Hence, it was 
feasible for a gland to be both cured and to have a 
new infection. For this reason, the status for each gland 
was independently defined as cured/not cured and no 
new infection/new infection. So to reflect the overall 
outcome for a gland, the final status for each gland was 
defined as no growth (i.e., both posttreatment samples 
were no growth), still infected (i.e., bacteria were iso-
lated from one or both posttreatment samples (even 
where the other sample was missing, contaminated, or 
no growth), or not able to be determined (i.e., both 
samples posttreatment were contaminated or missing or 
where one sample was missing or contaminated and the 
other was a no growth). For analysis of bacteriological 
cure, new infection rate and final status, cure was de-
fined at the lowest taxonomic level for which data were 
available. For example, where the pathogen isolated at 
the time of treatment was isolated to the species level, 
the posttreatment assessment of status was done at the 
same level. Conversely, where identification was only 
to the genus level (for example, where the isolate was 
defined as a CNS pretreatment), the same definition 
was applied for the posttreatment analyses. Note the 
comparison of distribution of bacteria between treat-
ment groups was undertaken at the broader group cat-
egorization of no growth, Staphylococcus aureus, CNS, 
streptococci, gram-negative rods, and others.
Data Handling and Analysis
At the time of enrollment the cows’ identity, age, 
clinical data, and previous SCC data in the current 
lactation (if any) were recorded into a purpose-built da-
tabase on a tablet. At each visit to the farm, AI dates, 
pregnancy test results, or additional treatment data 
were entered into the database. The date and 1 or 2 
reasons for each removal (i.e., death, cull, or sale) were 
recorded. Error trapping routines were included on the 
tablet database such that any out-of-range dates, ages, 
rectal temperatures, and so on could not be entered. 
Data from the tablet were transmitted to centralized 
database when the tablet had a Wi-Fi connection to 
the World Wide Web. Data were verified and any du-
plicate data excluded centrally.
The experimental unit for the study was the quarter 
(for bacteriological cure proportion) and the cow for 
fertility and removal outcomes.
The balance of treatments for age, calving date, and 
breed were compared using χ2 (for categorical variables) 
or 1-way ANOVA (for continuous variables).
Fertility outcomes of interest were defined as follows:
• Proportion of cows bred within 21 d of the vol-
untary waiting period: number of cows with an 
insemination within 21 d of voluntary waiting 
period/total number of enrolled cows. The volun-
tary wait period was the farmer-defined interval 
between calving and earliest time point at which 
a cow detected in estrus would be bred. Where a 
cow was bred before the voluntary waiting period, 
it was included in the numerator.
• Interestrus interval: intervals (d) between the first 
and second AI for cows having at least 2 AI.
• Calving to first insemination: the interval in days 
from calving to first AI.
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• Proportion of cows conceiving to first (or second 
and so on) AI: number of cows confirmed preg-
nant following the first (or second and so on) AI/
total number of cows receiving a first (or second 
and so on) AI.
• Services per animal or services per conception: 
sum of number of AI/total number of enrolled 
cows (or number of cows confirmed pregnant).
• Proportion of cows pregnant by 120 (or 200) days 
after calving: number of cows confirmed pregnant 
by d 120 (or d 200)/total number of enrolled cows.
• Final proportion of cows pregnant (overall preg-
nancy rate): number of cows confirmed pregnant/
total number of enrolled cows − cows with no 
AI − cows not pregnancy tested >30 d after last 
recorded AI.
• Calving to conception: the interval in days from 
calving to conception. 
The main predictor variable was treatment (i.e., 
treatment versus control). However, several other 
variables that were potential confounders were also 
evaluated. These variables included age (categorized 
into quartiles; <4, 4, 5, >5 yr old), site, number of in-
tramammary antibiotic treatments (1 to 4), CMT score 
at enrollment (coded as 0 + trace, 1, 2, 3), clot score 
at enrollment (0, 1, 2), rectal temperature (categorized 
into 1°C strata), bacteria species or genus present at 
enrollment (categorized as no growth, Staphylococcus 
aureus, CNS, streptococci, gram-negative rods, and 
others), bacteriological cure following treatment (yes/
no), DIM at enrollment (categorized into 30-d blocks), 
days between enrollment and first service (categorized 
into 30-d blocks), and season of the year (i.e., Janu-
ary to March, April to June, July to September, and 
October to December).
Descriptive analyses were performed to check for out-
lying values and inconsistencies. Initially, the bivariate 
associations between the outcome variables of interest 
(as above) and the predictor variables were examined 
using χ2 analysis for categorical variables and logistic 
regression for continuous variables. Those variables as-
sociated (i.e., P < 0.2) were then offered to a reverse 
stepwise procedure using a generalized linear model 
with a logit binomial structure and using likelihood 
ratio as the inclusion/exclusion criteria. Variables were 
removed if nonsignificant (P > 0.05), if they did not 
improve the goodness of fit as assessed using Akaike’s 
information criterion, or if the coefficient for the treat-
ment effect did not alter by >10%. Those variables 
in these models and treatment (by design) were then 
included in general estimating equation (GEE) models 
with cow and herd nested within site to account for 
the clustered nature of the data. The estimated mar-
ginal means for treatment and other main effects were 
calculated and the levels compared on a pairwise basis 
using the Bonferroni adjustment for multiple compari-
sons. First-order interactions between treatment and 
the other significant main effects were examined and 
included in the final model where P < 0.05. To as-
sess the suitability of the GEE models, the coefficients 
and P-values from the model of conception proportion 
to first insemination with treatment and age group as 
main effects were compared with those from a binary 
logistic regression model (i.e., not accounting for cow 
with herd or herd within regions clustering) and 2- (i.e., 
cow within herd) and 3- (cow within herd within region) 
level models in STATA (V14.1, College Station, TX). 
In all models, treatment was significant (P < 0.05) and 
the estimate of differences in proportion of first service 
conception rate was highly consistent (0.099, 0.102, 
0.104, and 0.109 higher for treatment than control cows 
in the GEE, binary logistic, and 2- and 3-level models, 
respectively). For speed of computation reasons, the 
GEE models were used. The intraclass correlations 
were calculated from null 2- and 3-level models to as-
sess clustering. The intraclass correlations were calcu-
lated to be 0.05 and 0.03 in the 2- and 3-level models, 
respectively. This low intraclass correlation indicates 
very little clustering and that most of the variation 
is occurring between cows and not between herds or 
regions.
The number of AI for all enrolled cows irrespective of 
final pregnancy status and the number of AI required 
for those cows confirmed pregnant were tested using 
the nonparametric independent samples median test.
Survival analysis techniques were used to investigate 
the effect of treatment on days from calving to first 
insemination, from calving to conception, and from 
calving to removal and from initiation of treatment to 
next antibiotic treatment (irrespective of indication). 
If herd owners chose not to breed a cow, these cows 
were included in the analyses as the analysis was on 
an intention to treat basis. Cows were censored at 300 
d after calving if they had failed to be inseminated or 
to conceive and had not been removed. For the ad-
ditional antibiotic usage analysis, cows were censored 
at 30 d postinitiation of treatment if they had not been 
re-treated with antibiotics (for any indication) within 
that time frame. Cows removed for other reasons (e.g., 
death, culling) within this time frame were censored at 
time for removal.
For the final removal analysis, a cow was defined as 
removed where the herd owner had provided a date of 
removal and categorized the removal as a death, cull, 
or sale. Where no record of removal, death, or culling 
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was provided for a cow, the cows’ ongoing presence in 
the herd was verified by investigators from electronic 
records, by phone call, or by on-farm verification of the 
cows’ presence. Some cows (n = 23) were not able to be 
verified as being present. In these cases, the last data 
point available for that cow was used as the right cen-
soring date. Data examined to determine the last date 
a cow was present included AI dates, pregnancy test 
dates, any additional treatment event dates, or sub-
sequent calving date. The interval from calving (and 
treatment) to the last date verified was calculated for 
every cow. Cows were right censored at either 300 d (if 
the cow was not removed) or earlier for those cows that 
were coded as having the event of interest (removal) 
<300 d.
Initially, Kaplan-Meier analyses were undertaken and 
variables associated (Breslow tests at levels of P < 0.2) 
were included in the multivariable modeling. Daily haz-
ard of conception (or removal) was estimated using a 
Cox’s proportional hazards model. Model building was 
in a forward manual step-wise manner, with variables 
retained in the model when likelihood ratio statistic 
was P ≤ 0.05, or when a change of >15% in the coef-
ficient of the treatment variable occurred. The data are 
presented as the mean and median days from calving 
to first breeding (or conception; from the Kaplan-Meier 
analyses) and graphically as the cumulative survival 
proportion by days after calving (or treatment). Ad-
ditionally, the HR from the final Cox’s proportional 
hazards models are presented. An HR of >1 indicates 
an increased probability of the event (e.g., pregnancy 
or removal) occurring.
The quarter-level SCC data were natural log-trans-
formed and effect of treatment on SCC at each time 
point (i.e., d 0, 14, and 21) and the change in SCC from 
d 14 to 0 and d 21 to 0 analyzed by one-way ANOVA. In 
all the cases, the data were homogenous (i.e., Levene’s 
test for homogeneity P > 0.15 for all comparisons). 
Removals to 300 d after treatment were analyzed at 
bivariate level (χ2) only. All analyses were undertaken 
in IBM SPSS Statistics version 22 (Chicago, IL).
Power Estimates
The study was designed to have sufficient power to 
demonstrate superiority of the treatment group over 
the control group in terms of first AI conception rate 
and culling proportion.
Thus, this was a superiority study with 
 h0 = μIVP = μCP; hA μIVP > μCP, 
where μ = the proportion of cows conceiving to first AI 
(or culled) in the treatment (μ IVP) and control (μ CP) 
groups, respectively, h0 = the null hypothesis, and hA = 
alternative hypothesis.
The reported first-service conception rates for cows 
in Europe vary between 36% and 56% (Loeffler et al., 
1999b; Klaas et al., 2004; Tenhagen et al., 2004; von 
Krueger and Heuwieser, 2010). The unweighted mean 
of these studies was 46%. Loeffler et al. (1999a) esti-
mated that cows with mastitis had a 12% decline in 
first service conception rate compared with those with-
out mastitis (i.e., 34% versus 46%). Similarly, Santos et 
al. (2004) found a 7% decline in first service conception 
rate where clinical mastitis was diagnosed before first 
insemination compared with no history of mastitis. We 
initially hypothesized that meloxicam would halve the 
loss in conception rate associated with clinical mastitis; 
hence the absolute difference in first service conception 
rate would be of order of 6 to 9.5%. If we assumed that 
the first service conception rate of a cow with clinical 
mastitis not treated with meloxicam was 30% and the 
first service conception rate of clinical cases treated 
with meloxicam was 40%, then we needed 280 cases 
per treatment group (assuming α = 0.05, β = 0.2, and 
a 1-sided test).
In an earlier study in New Zealand assessing the ef-
fect of meloxicam on removal (culling) rates (McDou-
gall et al., 2009), the removal percentages were 16 and 
28% (odds ratio = 0.42) for meloxicam-treated and 
control cows, respectively. Culling rates appear to be 
higher in Europe (e.g., 31% overall reported by Rajala-
Schultz and Gröhn, 1999b) relative to New Zealand 
(where approximately 20% of cows/yr are removed), 
and the relative risk of culling of cows with a history 
of clinical mastitis is about 1.5- to 2-fold higher than 
for nonmastitic cows. Thus, if we assumed the culling 
rates for cows without mastitis to be 25%, then 37% 
to 50% of mastitic cows were expected to be culled. If 
we assumed the culling rate of clinical mastitis cases 
without meloxicam treatment was 35% and that the 
odds ratio of culling was 0.7 (i.e., an absolute culling 
rate of 24%) with meloxicam, then we needed 220 cows 
per treatment group (assuming α = 0.05, β = 0.2, and 
a 1-sided test).
RESULTS
Cows Included
Five hundred and nine cows were initially enrolled 
into the study. No reproductive (AI dates, pregnancy 
test data, and so on) or additional treatment data were 
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provided for 4 cows at one site, and these cows were 
excluded from the reproductive analyses. Additionally, 
3 cows were excluded from the reproductive analyses 
because they had been confirmed pregnant before en-
rollment date and incorrectly enrolled. Thus, 502 cases 
were eligible for the reproductive analyses.
Group Balance
Treatment groups did not differ by allocation within 
site, age of cow, CMT, or clot scores at enrollment, 
bacterial species at enrollment, or the number of intra-
mammary treatments given (all P > 0.1; Table 1). The 
rectal temperature at the time of enrollment also did 
not differ between treatment groups [38.6°C (SD = 0.5) 
versus 38.7°C (SD = 0.5) for treatment versus control 
cows, respectively; P = 0.48]. Cows in the meloxicam 
group were enrolled on average 8 d later in lactation 
than the placebo group [49.7 d (SD = 35.8) versus 41.5 
d (SD = 35.2) for treatment versus control cows, re-
spectively; P = 0.01].
Additional Treatments after Enrollment
A total of 89/502 cows were treated with an addi-
tional antibiotic within 30 d of initiation of primary 
treatment. The number of glands and cows re-treated 
did not vary between treatment groups [41/250 (16.4%) 
versus 48/252 (19.0%) for treatment versus control, re-
spectively, P = 0.44].
A total of 6 cows (5 from the meloxicam group, 1 
from the control group) were culled (n = 3; one each 
for mastitis, production, and lameness) or died (n = 3) 
<30 d after initiation of treatment and were censored 
on the day of death or culling.
Bacteriology
No difference was found in the distribution of bacte-
riological groups between treatment groups at the time 
of enrollment (Table 1).
At the bivariate level, bacteriological cure was associ-
ated (P < 0.2) with treatment group [80/118 (67.8%) 
Table 1. Number (no.) and percentage (within treatment) of cows by treatment group for cows with mild to moderate mastitis treated with 
intramammary antibiotics and parenterally with either meloxicam or placebo1
Item  Category
Meloxicam
 
Placebo
P-valueNo. % No. %
Site 1 11 4.3 11 4.3 1.00
 2 28 11.1  28 10.9  
 3 8 3.2  9 3.5  
 4 2 0.8  2 0.8  
 5 11 4.3  11 4.3  
 6 60 23.7  60 23.4  
 7 19 7.5  20 7.8  
 8 55 21.7  55 21.5  
 9 19 7.5  20 7.8  
 10 40 15.8  40 15.6  
Age (yr) <4 97 39.4  97 38.3 0.16
 4 57 23.2  49 19.4  
 5 44 17.9  37 14.6  
 >5 48 19.5  70 27.7  
California Mastitis Test score d 0 0 + trace 6 2.4  8 3.1 0.82
1 56 22.1  63 24.6  
 2 112 44.3  112 43.8  
 3 79 31.2  73 28.5  
Clot score d 0 0 53 20.9  58 22.7 0.82
 1 121 47.8  124 48.4  
 2 79 31.2  74 28.9  
Bacteria d 0 No growth 69 31.7  73 32.3 0.26
 Staphylococcus aureus 9 4.1  11 4.9  
 CNS 24 11.0  32 14.2  
 Streptococci 49 22.5  50 22.1  
 Gram-negative rod2 34 15.6  25 11.1  
 Others 23 10.6  15 6.6  
 Mixed 10 4.6  20 8.8  
No. of intramammary tubes 1 3 1.2  7 2.7 0.53
 2 183 72.3  190 74.2  
 3 21 8.3  19 7.4  
 4 46 18.2  40 15.6  
1The P-values are derived from the bivariate analyses.
2Citrobacter species, Enterobacter species, Escherichia coli, Klebsiella species, Pasteurella species, Pseudomonas species, Serratia species.
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versus 67/119 (56.3%) for treatment versus control, 
respectively; Table 2], rectal temperature at the time 
of enrollment, and bacteria at the time of enrollment. 
Cure rate was not associated with the number of in-
tramammary treatments, the clot or CMT score at the 
time enrollment, the age of the cow, DIM at treatment, 
or the site.
In the final GEE model, bacteriological cure pro-
portion was associated with treatment and bacteria 
group. Cows treated with meloxicam had a higher 
bacteriological cure proportion than those treated with 
the control [0.66 (SE = 0.04) versus 0.50 (SE = 0.06) 
for treatment versus control, respectively; RR = 1.99 
(95% CI 1.17–3.40); P = 0.012]. Glands infected with 
Staphylococcus aureus had a lower bacteriological cure 
proportion than glands infected with other species or 
groups. Gram-negative rods and CNS had better cure 
proportion than other pathogens. No interaction was 
found of treatment by bacteria (P = 0.56).
A total of 198/382 (51.8%) of glands acquired a new 
intramammary infection. At the bivariate level, the rate 
of new infection was associated (P < 0.2) with site, clot 
score at enrollment, bacterial species at enrollment, 
cure rate, age, DIM at enrollment, and season. As cure 
rate was counfounded with treatment group, bacterial 
group at enrollment was used in the final model. In the 
final model, the new infection tended to be higher in 
cows treated with meloxicam than the control group 
[0.51 (95% CI 0.40 to 0.62) versus 0.44 (95% CI = 
0.37–0.52), for treatment versus control, respectively; 
P = 0.08]. New infection rates increased with age (P 
< 0.001), were highest in April to June (P < 0.001), 
and were lowest in glands infected with S. aureus at 
enrollment (P = 0.001).
Table 2. Outcome of glands infected at the time of diagnosis of clinical mastitis by treatment group for cows with mild to moderate mastitis 
treated with intramammary antibiotics and parenterally with either meloxicam or placebo1
Species/genus at enrollment
Cure 
 
New infection
Meloxicam
 
Placebo Meloxicam
 
Placebo
No Yes No Yes No Yes No Yes
Bacillus species 2 2   2  3 2  1 1
Citrobacter species  1     1 1    
CNS 2 3  1 5  2 3  4 2
Corynebacterium species  1   2  1   2  
Enterobacter cloacae  1      1    
Enterobacter species     1     1  
Enterococcus cecorum            
Enterococcus species 1 1  1 1  1 1  2 1
Escherichia coli 2 17  2 17  10 10  9 11
Klebsiella pneumoniae     1      1
2 bacterial species2 4 5  8 8  5 4  9 5
Mixed flora3       4 8  4 3
Mold           1
Pasteurella multocida 1       1    
Proteus species  1      1    
Prototheca species 1 2  2   1 2   1
Pseudomonas species     1     1  
Serratia marcescens 1 6  1   2 6  1  
Staphylococcus aureus 8 1  7 1  7 2  7  
Staphylococcus chromogenes  5  1 4   5  4 3
Staphylococcus haemolyticus  5  1 3  5   2 2
Staphylococcus sciuri  3   5  1 2  2 3
Staphylococcus simulans    2      2  
Streptococcus dysgalactiae ssp. dysgalactiae 3 5  2 8  4 4  2 7
Streptococcus species Lancefield-group G 3 3  5 3  5 2  4 3
Streptococcus uberis 7 16  15 5  11 16  11 10
Trueperella pyogenes    2      1  
Viridens streptococci    1      1  
Yeast 3 2  1   3 1   1
No growth       24 29  23 36
Total 38 80  52 67  90 101  93 91
1Cure was defined as not growing the bacteria present pretreatment at either of the posttreatment sampling time points. Where 2 bacterial spe-
cies were grown, cure was defined where neither species were grown at either of the posttreatment sampling points. New intramammary infec-
tion was defined as occurring either where a gland previously uninfected (no growth) subsequently isolated bacteria posttreatment, or where a 
different bacterial species was isolated posttreatment from that isolated pretreatment.
2Two bacterial species were cultured.
3More than 2 species were grown; that is, the sample was contaminated.
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The final bacteriological status was determined for 
397 of 509 (80%) glands. No difference was found ei-
ther at bivariate or multivariate level in proportion of 
glands that did not have an intramammary infection 
posttreatment (i.e., were pathogen free at both post-
treatment samplings) by treatment [56/189 (29.6%) 
versus 61/208 (29.3%) for treatment versus control; P 
= 0.97]. The only variable associated with the gland 
being pathogen free following treatment was whether 
the gland had cured [0.32 (SE = 0.04) for bacteriologi-
cally cured glands versus 0.20 (SE = 0.02) for glands 
not cured; P = 0.01].
SCC Pre- and Posttreatment
There was no difference in the Ln SCC at d 0, 14, or 
21 or in the difference between d 14 and 0 or d 21 and 
0 for treatment versus control (all P > 0.5; Table 3). 
The Ln SCC at d 14 (5.80 ± 0.15 versus 7.78 ± 0.22 for 
cured versus uncured glands, respectively; P < 0.001) 
and d 21 (5.66 ± 0.16 versus 7.78 ± 0.24 for cured ver-
sus uncured glands, respectively; P < 0.001) were lower 
in those glands in which bacteriological cure occurred. 
No treatment group by cure interactions were found for 
Ln SCC at d 14 or 21, or in the difference between d 14 
and 0 or d 21 and 0 (all P > 0.05).
Reproduction Outcomes
A summary of the fertility performance is presented 
in Table 4.
Proportion of Cows Bred Within 21 of the 
Voluntary Waiting Period. A total of 272 of the 
502 cows (54.2%) received AI within 21 d of the end of 
the voluntary waiting period. At the bivariate level, the 
likelihood a cow would receive AI was associated with 
site, number of intramammary treatments given, and 
the clot score at the time of enrollment. In the final 
GEE model, no effect was found of treatment on the 
proportion of cows that received AI [0.53 (SE = 0.02) 
versus 0.52 (SE = 0.02) for treatment versus control, 
respectively; P = 0.74]. Sites differed in the likelihood 
that a cow would receive AI (P < 0.001).
Inter-Estrous Intervals. Fewer cows treated with 
meloxicam had 18- to 24-d intervals between first and 
second AI (Table 4; Figure 1; P = 0.04).
Calving to First Insemination: Survival Analy-
sis. A total of 458 of the 502 cows (91.2%) had an 
AI by 300 d after calving. At the bivariate level, no 
difference was found between groups in the proportion 
of cows that had not received AI by 300 d after calv-
ing [19/249 (7.6%) versus 25/253 (9.9%) for treatment 
versus control, respectively]. The hazard of AI was 
associated with site, age category, CMT score at enroll-
ment, diagnosis of clinical mastitis before the voluntary 
waiting period, and the season of the year in which 
diagnosis occurred.
In the final multivariate (Cox’s) proportional hazards 
model, the hazard of AI varied among sites (P < 0.001). 
No effect was found of treatment on the hazard of first 
AI [HR 0.95 (95% CI = 0.79–1.14), P = 0.55; Figure 2].
Proportion of Cows Conceiving to First AI. 
A total of 126 of the 442 cows (28.5%) conceived to 
the first AI. Conception rate to first AI was associated 
(P < 0.2) at the bivariate level with site, treatment, 
age category, clot score at enrollment, and number of 
intramammary treatments. Days in milk at the time of 
treatment, DIM at first service, and interval between 
Table 3. The natural log (Ln) of SCC (×1,000 cells/mL) for quarters diagnosed with mild to moderate clinical 
mastitis and treated parenterally either with meloxicam or control
Item  Treatment No. Mean SD SE
95% CI
Low High
Ln SCC d 0  Meloxicam 144 8.02 1.69 0.14 7.74 8.30
  Control 152 8.03 1.68 0.14 7.76 8.30
  Total 296 8.03 1.68 0.10 7.83 8.22
Ln SCC d 14  Meloxicam 195 5.94 1.98 0.14 5.66 6.22
  Control 205 6.03 2.10 0.15 5.74 6.32
  Total 400 5.99 2.04 0.10 5.79 6.19
Ln SCC d 21  Meloxicam 194 5.94 2.12 0.15 5.64 6.24
  Control 203 5.90 2.19 0.15 5.59 6.20
  Total 397 5.92 2.15 0.11 5.70 6.13
Ln SCC d 14 to 01  Meloxicam 124 −2.12 2.16 0.19 −2.51 −1.74
  Control 134 −2.18 2.21 0.19 −2.55 −1.80
  Total 258 −2.15 2.18 0.14 −2.42 −1.88
Ln SCC d 21 to 01  Meloxicam 117 −2.21 2.31 0.21 −2.63 −1.79
  Control 132 −2.35 2.35 0.20 −2.75 −1.95
  Total 249 −2.28 2.33 0.15 −2.57 −1.99
1Difference in Ln SCC on d 14 (or d 21) and d 0.
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treatment and first service were not predictors of first 
AI conception proportion.
In the final GEE model, treatment with meloxicam 
was associated with an increased first AI conception 
proportion compared with the control [0.31 (SE = 0.02) 
versus 0.21 (SE = 0.02) for treatment versus control; 
RR = 1.68 (95% CI = 1.25–2.25); P < 0.01]. First ser-
vice AI proportion was lower in 5-yr-old and >5-yr-old 
cows compared with <4-yr-old cows (P < 0.01), and 
the conception proportion varied by site (P < 0.001).
Number of Inseminations. Over all cows, cows 
in the meloxicam group received fewer AI than those 
Table 4. Number of cows (No.+ve) and proportion (Propn) of cows or median and 95% confidence intervals for dichotomous and continuous 
measures of reproductive performance of cows with mild to moderate clinical mastitis treated with intramammary antibiotics and parenterally 
with either meloxicam or placebo (control)1
Parameter
Meloxicam
 
Control
 P-valueNo. +ve  Total  Propn No. +ve Total Propn
Dichotomous measure
 Bred by 3 wk VWP2 136 249 0.55 136 253 0.54 0.85
 Proportion returns 18 to 24 d3 37 144 0.26  62 170 0.36 0.04
 Conceive to AI #1 75 225 0.33  51 217 0.24 0.02
 Conceive to AI #2 46 144 0.32  47 170 0.28 0.41
 Conceive to AI #3 31 89 0.35  29 114 0.25 0.15
 Pregnant by d 120 104 249 0.42  84 253 0.33 0.05
 Pregnant by d 200 161 249 0.65  151 253 0.60 0.25
 Pregnant final 192 224 0.86  189 216 0.88 0.58
Continuous measure
Meloxicam Control
Interval (d)
Median
95% CI
Median
95% CI
Low High Low High
  Calve to first AI 77 73 81 78 75 81 0.45
  Calve to conception 132 122 142 154 136 172 0.26
1The P-values are from χ2 (dichotomous) or Kaplan-Meier (continuous) univariable analyses.
2Voluntary waiting period.
3Proportion of cows with an inter-estrus interval of 18 to 24 d/all cows with an inter-estrus interval.
Figure 1. The interval (d) between the first and second AI by 
treatment group: meloxicam (top) or control (bottom).
Figure 2. The cumulative survival (i.e., not receiving AI) for cows 
diagnosed with mild to moderate clinical mastitis treated with intra-
mammary antibiotics and parenterally with either meloxicam (solid 
line) or control (dashed line).
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in the control group [2.46 (95% CI = 2.20–2.72; me-
dian = 2) versus 2.70 (95% CI 2.45–2.96; median = 2) 
for treatment versus control, respectively; P = 0.04]. 
Among those cows confirmed pregnant, the number 
of AI required to achieve conception was lower among 
those cows treated with meloxicam compared with the 
untreated controls [2.43 (95% CI = 2.17–2.69; median 
= 2) versus 2.92 (95% CI 2.65–3.19; median = 2) for 
treatment versus control, respectively; P = 0.009].
Proportion of Cows Pregnant by 120 d Af-
ter Calving. A total of 188 of 502 (37.5%) of cows 
were confirmed pregnant by 120 d after calving. At 
the bivariate level, the proportion of cows pregnant by 
120 d was associated (P < 0.2) with treatment, rectal 
temperature at enrollment, age group, and whether the 
cow had been diagnosed with clinical mastitis before or 
after first service.
In the final GEE model, more treatment than control 
cows were pregnant by 120 d after calving [0.40 (SE 
= 0.01) versus 0.31 (SE = 0.01); P < 0.001], and the 
proportion pregnant varied among sites (P < 0.001) 
and among age groups (P < 0.001).
Proportion of Cows Pregnant by 200 d After 
Calving. A total of 312 of 502 (62.2%) of cows were 
confirmed pregnant by 200 d after calving. At the bi-
variate level, the proportion of cows pregnant by 200 d 
was associated (P < 0.2) with age group, whether the 
cow had been diagnosed with clinical mastitis before 
or after first insemination and season of year in which 
diagnosis occurred.
In the final GEE model, no difference was found 
between treatments in proportion of cows pregnant by 
200 d after calving [0.61 (SE = 0.03) versus 0.56 (SE 
= 0.02); P = 0.14], but the proportion pregnant varied 
among age groups (P < 0.001) and season of the year 
in which enrollment occurred (P < 0.001) with a lower 
proportion in April to June and higher proportion in 
July to September compared with October to Decem-
ber.
Final Proportion of Cows Pregnant (Overall 
Pregnancy Rate). A total of 62 cows were either not 
bred at all (n = 44), did not have any pregnancy diag-
nosis undertaken (n = 16), or did not have pregnancy 
diagnosis undertaken after the last recorded insemina-
tion (n = 2). A tendency was found for less of the 
meloxicam than control cows to have an unknown final 
pregnancy status [25/249 (0.10) versus 37/253 (0.15) 
for treatment versus control, respectively; P = 0.12]. 
No difference was found among groups in the propor-
tion of cows finally defined as pregnant [192/224 (0.86) 
versus 189/216 (0.88) for treatment versus control, 
respectively; P = 0.58].
Calving to Conception Interval. At the bivariate 
(Kaplan-Meier) level, the hazard of pregnancy was as-
sociated (P < 0.2) with bacteria group at enrollment, 
age category, timing of diagnosis and treatment rela-
tive to AI, and season in which diagnosis occurred. The 
median interval from calving to conception was 132 (SE 
= 5) versus 154 (SE = 9) d for the treatment versus 
control, respectively (P = 0.26).
Hazard of Pregnancy. In the final Cox’s propor-
tional hazards model, the hazard of pregnancy tended 
[HR = 1.21 (95% CI 0.98–1.50); P = 0.08] to be higher 
for treatment than control cows (Figure 3a). Cows <4 
yr old conceived more quickly than cows 5 or >5 yr old 
(P < 0.001; Figure 3b). Cows diagnosed with mastitis 
before the first insemination were slower to conceive 
than those diagnosed after first insemination (P < 
0.001; Figure 3c). Site was included in the model but 
was not significant (P = 0.42).
Removals. A total of 158 of 505 (31.3%) cows were 
recorded as having died, been culled, or been removed 
during the study. The mean day of removal was 294 d 
after calving (median = 283 d; SD = 160 d; range = 
5 to 704 d) and 82 (51.9%) and 76 (48.1%) of the 158 
cows were removed <300 and ≥300 d after calving, 
respectively.
At the bivariate level, no difference was found in the 
proportion of cows removed, died, or sold <300 d of 
treatment between the treatment groups (Table 5; P 
= 0.97). Additionally, the reasons provided for removal 
did not differ among those cows culled <300 d after 
treatment (Table 6; P = 0.84).
Survival to 300 d Posttreatment. The survival to 
300 d after treatment did not differ among treatment 
groups at the bivariate level (Figure 4; P = 0.24). Sur-
vival was affected by age (P < 0.01) and the clot score 
at the time of enrollment (P = 0.03).
In the final Cox’s proportional hazards model, treat-
ment was not associated with risk of removal [HR = 
1.22 (95% CI = 0.82–1.83), P = 0.32], whereas younger 
cows (i.e., <4 yr old) were less likely to be removed 
than older cows [HR = 2.25 (95% CI = 1.24–4.10), HR 
= 3.12 (95% CI = 1.71–5.68), and HR = 2.79 (95% 
CI = 1.60–4.88) for 4-, 5-, and >5-yr-old cows, respec-
tively, relative to <4-yr-old cows; P < 0.001].
DISCUSSION
This study demonstrated that addition of meloxicam 
to antimicrobial treatment of mild to moderate clini-
cal mastitis resulted in an increased first AI concep-
tion proportion and an increased proportion of cows 
pregnant by 120 d after calving. Additionally, at the 
univariable level, meloxicam-treated cows had fewer 18 
to 24 d returns and fewer inseminations were needed to 
achieve conception. The hazard of pregnancy tended to 
be higher for cows treated with meloxicam.
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This study was undertaken across 8 regions in 6 
countries across Europe. As such, it is likely to have a 
high level of external validity. Randomization of cows 
to treatment was undertaken at region (site) rather 
than herd level. This randomization approach was used 
because it was believed that only a small numbers of 
cases would be enrolled in any individual herd and 
the time over which it was likely take to enroll cases 
would be such that the variability between herd within 
a region within a short time period (a few weeks) may 
be less than the variability within herd across seasons 
and across an extended period of time. Due to the 
hierarchal nature of the data (i.e., cow within herd 
within region), it is feasible that an unequal alloca-
tion of treatment and controls across herds differing 
in reproductive performance could potentially result in 
Figure 3. Cumulative survival (i.e., not pregnant) of cows with mild to moderate mastitis treated with intramammary antibiotics and par-
enterally with either with meloxicam or placebo by (a) treatment group (meloxicam = solid line; control = dashed line), (b) age group (<4 = څ; 4 = , 5 = Δ, >5 = 	), and (c) diagnosis and treatment of clinical mastitis before (solid line) or after first AI (dashed line).
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bias, such that effects ascribed to treatment may in fact 
be due to herd level effects. In a study of reproductive 
performance of across 3,207 lactations in 1,570 herds, 
cows in 50 herds in 5 geographic regions, it was found 
that 86% of the variation in reproductive performance 
was at the lactation level, with only 7, 6, and 2% of the 
variability of cow, herd, and regional levels, respectively 
(Dohoo et al., 2001). The current study also found low 
intraclass correlations, suggesting that the great major-
ity of variation was occurring between animals and not 
between herds and regions. Thus, even if by chance 
allocation was unequal of treatment and control to 
herds of differing overall reproductive performance, the 
effects of the cow are more important in determining 
outcome than the herd or regional level effects. Further 
support for this was found in that the coefficients for 
the effect sizes were very similar whether clustering 
was accounted for or not. That is, models that did or 
did not account for the hierarchical nature of the data 
provided very similar estimates of first service concep-
tion proportion. If significant confounders were present 
at herd or regional level, it may have been expected 
that the significance or effect sizes, or both, associated 
with treatment would be variable among these models. 
So whereas herd level management factors may influ-
ence reproductive performance and hence increase the 
variability in the outcome measures, this variability 
may be no more than the between lactation, cow, or 
herd variability over a short period. At a region level, 
the herds were clients of one veterinary business, and 
hence advice, programs, and procedures would likely be 
consistent for reproductive management across these 
groups of herds. Taken together, these data suggest 
that although allocation bias may have occurred due to 
the experimental design, the likelihood that this would 
have resulted in errors of inference (that is, falsely 
concluding the presence of a treatment effect when in 
reality one was not present, or vice versa) or biases in 
the estimates of the size of the treatment effect appears 
low.
Several epidemiological studies have demonstrated 
that mastitis reduces conception proportion (Santos 
et al., 2004; Lavon et al., 2011), increases the number 
of services required per conception, and increases the 
interval from calving to conception (Barker et al., 1998; 
Schrick et al., 2001). Mastitis is also associated with 
altered inter-estrus intervals (Moore et al., 1991). The 
current study has demonstrated that treatment with 
Table 5. Number (no.) and proportion (Propn) of cows listed as culled, died, or sold within 300 d after 
treatment of cows with mild to moderate mastitis treated with intramammary antibiotics and parenterally 
with either meloxicam or placebo
Item
Meloxicam  Control
Total 
No.No. Propn No. Propn
Not removed 215 0.86 208 0.82 423
Culled 29 0.12 39 0.15 68
Died 2 0.01 2 0.01 4
Sold 5 0.02 5 0.02 10
Total 251  254   
Table 6. The primary reason for removal of cows within 300 d 
after treatment of cows with mild to moderate mastitis treated with 
intramammary antibiotics and parenterally with either meloxicam or 
control
Primary reason Meloxicam Control Total
Unknown 0 1 1
Low milk yield 7 7 14
Mastitis 10 12 22
Reproductive failure 9 9 18
Udder breakdown 1 3 4
Other 9 14 23
Total 36 46 82
Figure 4. Cumulative survival (i.e., not died, culled, sold) for cows 
with mild to moderate clinical mastitis treated with intramammary 
antibiotics and parenterally with either with meloxicam (solid line) or 
control (dashed line).
Journal of Dairy Science Vol. 99 No. 3, 2016
MELOXICAM IMPROVES FERTILITY IN COWS WITH MASTITIS 2039
meloxicam ameliorated some of the negative effects of 
mastitis on reproductive performance.
Although it has previously been demonstrated that 
mastitis is associated with an extended calving to first 
AI intervals (Barker et al., 1998; Schrick et al., 2001; 
Huszenicza et al., 2005) and a reduced probability of 
expressing estrus (Hockett et al., 2005; Lavon et al., 
2011), in this study no effect was found of treatment 
on the interval from calving to first AI or the propor-
tion of cows receiving AI by 21 d after the end of the 
voluntary waiting period. This study did not directly 
assess the probability of expression of estrus associated 
with ovulation.
The bovine mammary gland produces PGF2α (Hansel 
et al., 1976) and increases in PGF2α occur in milk from 
cows with clinical mastitis (Anderson et al., 1986). 
Challenge studies have demonstrated that LPS increas-
es circulating concentrations of prostaglandins (includ-
ing PGF2α), which shortens the lifespan of the corpus 
luteum (Giri et al., 1990). A similar increase in PGF2α 
was found after mastitis induction with Streptococcus 
uberis, indicating that this is not only a gram-negative 
effect (Hockett et al., 2000). Early luteolysis or early 
embryo resorption may alter inter-ovulatory and hence 
inter-estrus intervals. Pregnancy recognition occurs ap-
proximately 16 d after insemination and is dependent 
on a functional corpus luteum. Hence, if mastitis were 
to shorten luteal lifespan, pregnancy recognition and 
conception have an increased likelihood of failure. The 
lower proportion of 18 to 24 d returns suggests that 
meloxicam may have a protective effect on luteal func-
tion by reducing PGF2α concentrations.
Mastitis may also affect the hypothalamus-pituitary 
axis. Some cows challenged with Streptococcus uberis 
had reduced LH pulse frequency, had reduced estradiol 
concentrations, and did not express estrus or ovulate 
(Hockett et al., 2005). Those authors hypothesized that 
the effects of S. uberis on estrus expression were via in-
hibitory effects of inflammatory cytokines on pituitary 
LH release, independent of any effects on prostaglandin 
concentrations. Additionally, evidence indicates that 
mastitis affects follicular steroidogenesis, which causes 
delay in, or failure of, ovulation (Lavon et al., 2011). 
This may be mediated via cytokines as IL1-β, IL-2, 
TNFα, and IFNα have been shown to inhibit estra-
diol production by granulosa cells in vitro (Spicer and 
Alpizar, 1994) and direct effects of LPS on estradiol 
concentrations have been demonstrated (Herath et al., 
2007). Thus mastitis may be having negative effects 
on reproduction via mechanisms independent of pros-
taglandin. Evidence from in vitro studies suggests that 
NSAID can suppress production of some pro-inflam-
matory cytokines including IL-1 and IL-6 (Jiang et al., 
1998; Berg et al., 1999).
Clinical mastitis occurring soon after insemination 
has been associated with greater negative effects on 
reproductive performance than clinical mastitis before 
insemination (Santos et al., 2004). When clinical mas-
titis occurred any time between 14 d before, to 35 d 
after, AI was associated with a lower conception rate 
(Hertl et al., 2010), indicating that a closer temporal 
relationship between mastitis and AI has a greater 
negative effect. However, in the current study, no as-
sociation was found between timing of clinical mastitis 
and AI conception rate, nor did the timing of diagnosis 
of clinical mastitis and treatment relative to the time 
of AI modulate the treatment effect. This conclusion 
was reached by including the interval treatment and 
insemination as a main effect and then specifically 
testing whether the effect of treatment varied with dif-
fering intervals between treatment and AI by testing 
the treatment by time interaction for the key fertil-
ity outcomes. In no case did the interaction term for 
treatment by time appear in a final model. Although 
the power to find such an interaction was limited by 
the study size, the inference from the current study is 
that the effect of meloxicam is similar irrespective of 
the timing of treatment relative to AI. The duration 
of effect of the NSAID treatment, however, appears to 
be longer than that associated with a reduced PGF2α 
concentrations. Thus, it appears likely that some other, 
longer term mechanism, or an additive effect of multiple 
mechanisms, is operating. Chronic effects of mastitis on 
follicular dynamics have been demonstrated (Lavon et 
al., 2011), and hence if NSAID were to ameliorate the 
initial effects of mastitis, longer term negative effects 
may be reduced. This is demonstrated by the fact the 
treatment affected first service conception rate and the 
proportion of cows pregnant to d 120 postpartum, even 
where the interval between treatment and insemina-
tion was weeks to months in some cases. Although not 
significant, the treated cows had a higher proportion of 
cows pregnant by d 200 postpartum, but this is likely 
due to the faster rate of conception early postpartum.
A previous study investigating the effect of addi-
tion of meloxicam to antimicrobial therapy of mild to 
moderate mastitis found that inclusion of meloxicam 
resulted in a reduced probability of removal (McDou-
gall et al., 2009). Mastitis has been associated with 
an increased risk of culling, irrespective of the stage 
of lactation at which it occurs (Beaudeau et al., 
1995; Gröhn et al., 1997; Rajala-Schultz and Gröhn 
1999a,b). The risk of culling associated with mastitis 
may be due to direct effects of the disease and its 
treatment or due to reduced production or increased 
risk of failing to conceive. Reproductive status is the 
single most important factor in culling decisions and 
failure to conceive at first AI or an extended interval 
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from calving to conception increase the risk of cull-
ing (Beaudeau et al., 1995). However, once conception 
has occurred, risk of culling is decreased (Gröhn et al., 
1998). Across the entirety of the current study, 31% 
of cows were culled or died. A total of 31% of Finnish 
Ayrshire cows from the entire population (independent 
of preceding disease status) were removed each lacta-
tion (Rajala-Schultz and Gröhn, 1999a). It had been 
expected that clinical mastitis would increase culling 
rate compared with cows within mastitis in the current 
study, but as culling data from the rest of the popula-
tion in enrolled herds was not collected, this could not 
be verified. The current study found a nonsignificant 
4% reduction in the proportion of removals following 
meloxicam compared with untreated control cows in 
the 300 d postcalving. By this stage, only 18% of the 
control cows and 14% of the treatment cows had been 
removed. In the continuous calving systems used by all 
herds in the current study, almost half the cows that 
were removed during that lactation were removed more 
than 300 d after calving. Thus, the decision during the 
design phase of the study to right-censor removals at 
300 d may have led to an underestimate of the effect of 
treatment on this outcome. A potential explanation for 
the nonsignificance of meloxicam treatment effect on 
removal by 300 d compared with the significant finding 
in the previous study (McDougall et al., 2009) is that 
in the latter study, which was undertaken in season-
ally calving herds, those cows not conceiving in the 
12- to 14-wk breeding period were removed at the end 
of the lactation which is commonly <300 d. In contrast, 
cows in the current study remained in the herds, in 
some cases well beyond 300 d, even if they had failed 
to conceive, presumably because farm owners believed 
these animals were still producing sufficient milk to be 
economical.
This appears to be the first study that has demon-
strated an increased bacteriological cure rate of mild 
to moderate clinical mastitis cases following treatment 
with an NSAID. Positive benefits of NSAID in terms 
of resolution of inflammation associated with mastitis 
have been demonstrated (Vangroenweghe et al., 1995). 
Meloxicam may be acting by reducing the degree of 
udder edema and swelling (Fitzpatrick et al., 2013), 
potentially resulting in improved distribution of the an-
timicrobial in the quarter. Alternatively, its effects may 
be being modulated indirectly via improved host re-
sponse associated with earlier return to rumination, or 
an increased DMI as has been previously demonstrated 
in some (Yeiser et al., 2012) but not all (Fitzpatrick et 
al., 2013) studies using NSAID treatment of mastitis.
It has previously been demonstrated that meloxicam 
treatment of clinical mastitis results in lower SCC at 
quarter level 2 to 3 wk after treatment (McDougall 
et al., 2009). The current study did not replicate that 
finding. Several explanations are possible for this. 
The previous study was undertaken in pasture-based 
systems, and the pathogen distribution was different. 
Additionally, in the current study the proportion of 
glands that were uninfected following treatment did not 
differ between groups. So, although meloxicam resulted 
in higher bacteriological cure, the higher new infection 
rate posttreatment resulted in the same prevalence of 
IMI posttreatment, resulting in no difference in SCC.
CONCLUSIONS
Use of the nonsteroidal anti-inflammatory drug 
meloxicam, in addition to antimicrobial therapy for 
treatment of mild to moderate cases of clinical mastitis, 
results in a higher probability of bacteriological cure, 
and improved fertility in terms of higher conception 
to first service, higher probability of pregnancy by 120 
d postcalving, a reduced number of inseminations re-
quired to achieve pregnancy and a tendency to have a 
shorter calving to conception interval.
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